Melanoma of the skin is now the third most commonly diagnosed cancer in the U.S. Diagnoses of melanoma are six times as high today as they were 40 years ago.
While incidence of melanoma has been rising steeply, melanoma mortality has been generally stable.
In a Sounding Board article, published in The New England Journal of Medicine, H. Gilbert Welch MD, MPH, Senior Investigator, Center for Surgery and Public Health, Brigham and Women's Hospital and colleagues present evidence for why they believe that increased diagnostic scrutiny is the primary driver of the rapid rise in melanoma diagnoses.
"Melanoma is now the posterchild for overdiagnosis," said Welch. "Although the conventional response has been to recommend regular skin checks, it is far more likely that more skin checks are the cause of the epidemic - not its solution."
Among many examples, Welch and co-authors describe a study in which nine dermatopathologists reviewed skin-biopsy specimens used for diagnosis 20 years earlier.
Many of the specimens previously diagnosed as benign were now diagnosed as melanoma.
Welch and co-authors also share data showing that among the Medicare population, the proportion of beneficiaries biopsied increased every year from 2004 to 2017, nearly doubling over that time.
Over the same period, the incidence of melanoma in adults 65 and older also doubled.
The authors point out that there are many potential harms in over-diagnosing melanoma, from the immediate - scarring, wound infection, out-of-pocket costs - to longer term effects such as impeding access to care for people with symptomatic skin diseases.
"Despite the best of intentions by all parties, increased diagnostic scrutiny can produce a cycle of increasing overdiagnosis and intervention in any disease with a reservoir of subclinical forms. Melanoma is no exception," the authors write. "The economic disruption caused by Covid-19 obliges clinicians to protect people from the financial stress of needlessly being turned into a patient."
Source: Brigham and Women's Hospital
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.